ALS drug trial pulled before it even started
NCT ID NCT03474263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test an experimental drug called IC14 in people with rapidly progressing ALS. The drug was given by IV over two weeks, and brain scans measured inflammation. However, the trial was withdrawn before enrolling any participants, so no data on safety or effectiveness were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IC14 (a monoclonal antibody targeting CD14)
- What this could lead to
- If it worked, this could point toward a treatment that slows ALS by reducing brain inflammation.
- What could go wrong
- This trial was withdrawn before enrolling anyone, so no results exist. It was a small, early-phase study focused on biomarkers, not on proving the drug helps patients feel better or live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Brisbane & Women's Hospital
Herston, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body